Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC. Materials and Methods Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively. Results Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patients was 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor–positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti–HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease. Conclusion Anti–HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted.
Abstract
Purpose Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC. Materials and Methods Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively. Results Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patients was 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor–positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti–HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease. Conclusion Anti–HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted.
참고문헌 (24)
- Ravdin PM, "The decrease in breast-cancer incidence in 2003 in the United States", N Engl J Med, 356, pp.1670~1674 (2007)
- Stang A, "Decline in breast cancer incidence in the United States : what about male breast cancer?", Breast Cancer Res Treat, 112, pp.595~596 (2008)
- Speirs V, "The rising incidence of male breast cancer", Breast Cancer Res Treat, 115, pp.429~430 (2009)
- Annual report of cancer statistics in Korea in 2012, "Ministry of Health and Welfare; Korea Central Cancer Registry;National Cancer Center", National Cancer Center, ~ (2012)
- Baek JM, "Male breast cancer", J Breast Cancer, 8, pp.123~127 (2005)
- 노동영, "남성 유방암의 임상병리학적 특징", Journal of Breast Cancer, 10(3), pp.211~216 (2007), 한국유방암학회
- Lee PC, "Clinical features of the male breast cancer-13 cases", J Korean Breast Cancer Soc, 7, pp.193~198 (2004)
- Gomez-Raposo C, "Male breast cancer", Cancer Treat Rev, 36, pp.451~457 (2010)
- Fentiman IS, "Male breast cancer", Lancet, 367, pp.595~604 (2006)
- Miao H, "Incidence and outcome of male breast cancer : an international population-based study", J Clin Oncol, 29, pp.4381~4386 (2011)
- Scott-Conner CE, "An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients", Surgery, 126, pp.775~780 (1999)
- Ioka A, "Survival of male breast cancer patients : a population-based study in Osaka, Japan", Jpn J Clin Oncol, 36, pp.699~703 (2006)
- Nahleh ZA, "Male breast cancer in the veterans affairs population : a comparative analysis", Cancer, 109, pp.1471~1477 (2007)
- Hill A, "Localized male breast carcinoma and family history : an analysis of 142 patients", Cancer, 86, pp.821~825 (1999)
- Ottini L, "Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients : results from a collaborative multicenter study in Italy", Breast Cancer Res Treat, 134, pp.411~418 (2012)
- Onami S, "Male breast cancer : an update in diagnosis, treatment and molecular profiling", Maturitas, 65, pp.308~314 (2010)
- Ottini L, "BRCA1", BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany : a population-based study in central Italy, 2009, pp.116, 577~586
- Park HL, "Male breast cancer-10 cases", J Korean Breast Cancer Soc, 6, pp.303~307 (2003)
- Jaiyesimi IA, "Carcinoma of the male breast", Ann Intern Med, 117, pp.771~777 (1992)
- Giordano SH, "Efficacy of anastrozole in male breast cancer", Am J Clin Oncol, 25, pp.235~237 (2002)
- Mauras N, "Estrogen suppression in males : metabolic effects", J Clin Endocrinol Metab, 85, pp.2370~2377 (2000)
- Zagouri F, "Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer : a case series", Br J Cancer, 108, pp.2259~2263 (2013)
- Di Lauro L, "Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer : results from a pooled analysis", J Hematol Oncol, 8, pp.53~ (2015)
- "NCCN Clinical Practice Guidelines in Oncology Breast Cancer" (2015)[URL]